Yue‐Rong Ma

583 total citations
15 papers, 476 citations indexed

About

Yue‐Rong Ma is a scholar working on Molecular Biology, Nephrology and Complementary and alternative medicine. According to data from OpenAlex, Yue‐Rong Ma has authored 15 papers receiving a total of 476 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 3 papers in Nephrology and 3 papers in Complementary and alternative medicine. Recurrent topics in Yue‐Rong Ma's work include Chronic Kidney Disease and Diabetes (2 papers), Nephrotoxicity and Medicinal Plants (2 papers) and Neurological Disease Mechanisms and Treatments (1 paper). Yue‐Rong Ma is often cited by papers focused on Chronic Kidney Disease and Diabetes (2 papers), Nephrotoxicity and Medicinal Plants (2 papers) and Neurological Disease Mechanisms and Treatments (1 paper). Yue‐Rong Ma collaborates with scholars based in China and Japan. Yue‐Rong Ma's co-authors include Ichiro Shimizu, Hitoshi Hori, T. HORIE, Susumu Ito, Norifumi Kawada, Y. Mizobuchi, Fei Liu, Yoichiro Nakai, Sakae Amagaya and Masako Shiba and has published in prestigious journals such as Hepatology, Molecules and Medicine.

In The Last Decade

Yue‐Rong Ma

15 papers receiving 466 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yue‐Rong Ma China	9	159	124	114	111	56	15	476
Rehab S. Abdelrahman Egypt	16	148 0.9×	94 0.8×	93 0.8×	160 1.4×	47 0.8×	28	582
Yinxiao Jiang China	12	161 1.0×	139 1.1×	59 0.5×	122 1.1×	88 1.6×	17	489
Ahmed A. Shaaban Egypt	14	173 1.1×	83 0.7×	69 0.6×	80 0.7×	36 0.6×	31	497
Xinyu Deng China	13	201 1.3×	127 1.0×	34 0.3×	103 0.9×	49 0.9×	23	513
Jae Hyeon Park South Korea	16	197 1.2×	82 0.7×	50 0.4×	83 0.7×	26 0.5×	33	570
Xudong Hu China	17	253 1.6×	153 1.2×	73 0.6×	121 1.1×	43 0.8×	44	663
Xinyan Xue China	15	193 1.2×	124 1.0×	72 0.6×	103 0.9×	48 0.9×	28	548
Quan Jin China	19	366 2.3×	159 1.3×	73 0.6×	106 1.0×	40 0.7×	33	694
Musen Lin China	11	298 1.9×	127 1.0×	56 0.5×	90 0.8×	34 0.6×	17	512
Jun Kai China	12	242 1.5×	95 0.8×	45 0.4×	86 0.8×	53 0.9×	17	384

Countries citing papers authored by Yue‐Rong Ma

Since Specialization

Citations

This map shows the geographic impact of Yue‐Rong Ma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yue‐Rong Ma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yue‐Rong Ma more than expected).

Fields of papers citing papers by Yue‐Rong Ma

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yue‐Rong Ma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yue‐Rong Ma. The network helps show where Yue‐Rong Ma may publish in the future.

Co-authorship network of co-authors of Yue‐Rong Ma

This figure shows the co-authorship network connecting the top 25 collaborators of Yue‐Rong Ma. A scholar is included among the top collaborators of Yue‐Rong Ma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yue‐Rong Ma. Yue‐Rong Ma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Zhang, Yaodan, et al.. (2024). Oridonin Attenuates Diabetes‑induced Renal Fibrosis via the Inhibition of TXNIP/NLRP3 and NF‑κB Pathways by Activating PPARγ in Rats. Experimental and Clinical Endocrinology & Diabetes. 132(10). 536–544. 1 indexed citations

Zhang, Yaodan, et al.. (2022). Chronic kidney disease and NLRP3 inflammasome: Pathogenesis, development and targeted therapeutic strategies. Biochemistry and Biophysics Reports. 33. 101417–101417. 34 indexed citations

Gu, Wei, et al.. (2022). Ferroptosis-Related Genes Are Candidate Diagnostic and Prognostic Biomarkers for Skin Cutaneous Melanoma. Biomarkers in Medicine. 16(3). 179–196. 2 indexed citations

Wei, Huiting, et al.. (2022). ShenKang Injection Attenuates Renal Fibrosis by Inhibiting EMT and Regulating the Wnt/β-Catenin Pathway. Evidence-based Complementary and Alternative Medicine. 2022. 1–15. 15 indexed citations

Ma, Yue‐Rong, et al.. (2022). Losartan ameliorates renal interstitial fibrosis through metabolic pathway and Smurfs-TGF-β/Smad. Biomedicine & Pharmacotherapy. 149. 112931–112931. 36 indexed citations

Liu, Wei, et al.. (2022). Performance of Multiparametric Models in Patients With Brugada Syndrome: A Systematic Review and Meta-Analysis. Frontiers in Cardiovascular Medicine. 9. 859771–859771. 2 indexed citations

Chen, Xian, et al.. (2022). Shenkang Injection for Treating Renal Fibrosis-Metabonomics and Regulation of E3 Ubiquitin Ligase Smurfs on TGF-β/Smads Signal Transduction. Frontiers in Pharmacology. 13. 849832–849832. 10 indexed citations

Ma, Yue‐Rong, et al.. (2022). Interleukin-33/ Suppression of Tumorigenicity 2 in Renal Fibrosis: Emerging Roles in Prognosis and Treatment. Frontiers in Physiology. 12. 792897–792897. 15 indexed citations

Ma, Li, Mengmeng Zhang, Rong Zhao, et al.. (2021). Plant Natural Products: Promising Resources for Cancer Chemoprevention. Molecules. 26(4). 933–933. 89 indexed citations

10.

Chen, Yan-Kun, et al.. (2020). A review on the efficacy and mechanism of action of Shenkang injection against chronic kidney disease. Biomedicine & Pharmacotherapy. 132. 110833–110833. 26 indexed citations

11.

Gong, Daoyin, et al.. (2020). Renal protective effects of astragaloside IV, in diabetes mellitus kidney damage animal models: A systematic review, meta-analysis. Pharmacological Research. 160. 105192–105192. 28 indexed citations

12.

Yu, Guang, et al.. (2020). The efficacy of taking traditional Chinese medicine orally in renal interstitial fibrosis. Medicine. 99(38). e22181–e22181. 5 indexed citations

13.

Yu, Guang, et al.. (2020). The Efficacy of Taking Traditional Chinese Medicine Orally In Renal Interstitial Fibrosis: Protocol for A Systematic Review and Meta-Analysis. 1 indexed citations

14.

Shimizu, Ichiro, Yue‐Rong Ma, Y. Mizobuchi, et al.. (1999). Effects of Sho–Saiko–To, A Japanese Herbal Medicine, on Hepatic Fibrosis in Rats. Hepatology. 29(1). 149–160. 209 indexed citations

15.

Xu, Xiaoyu, et al.. (1996). Clinical observation of Qi deficiency syndrome in 72 patients with chronic obstructive pulmonary disease treated with Yiqi Mianyi Granule. Chinese Journal of Integrative Medicine. 2(3). 170–173. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact